Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274638 · ClinicalTrials.gov registry record · Phase 4
PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 805
- Enrollment target
NCT00274638 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 805 participants.
The verdict
NCT00274638, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 805 participants
- Enrollment target
Study Summary
To demonstrate that Telmisartan combined with Hydrochlorothiazide (MICARDIS® HCT) is superior to Losartan with Hydrochlorothiazide (Hyzaar®) in lowering blood pressure in mild-moderate hypertensives.
Interventions
- DRUG Telmisartan & Hydrochlorothiazide
- DRUG Losartan & Hydrochlorothiazide
- PROCEDURE ABPM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 805 participants |
| Start Date | 2002-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274638
The ClinicalTrials.gov registry entry for NCT00274638 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 805 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Telmisartan & Hydrochlorothiazide is the first listed.
NCT00274638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274638 about?
NCT00274638 is a clinical study titled "PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)". To demonstrate that Telmisartan combined with Hydrochlorothiazide (MICARDIS® HCT) is superior to Losartan with Hydrochlorothiazide (Hyzaar®) in lowering blood pressure in mild-moderate hypertensives.
What is the current status of trial NCT00274638?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 805 participants. The study started on 2002-07.
What interventions are being tested in trial NCT00274638?
The interventions under investigation include: Telmisartan & Hydrochlorothiazide (DRUG), Losartan & Hydrochlorothiazide (DRUG), ABPM (PROCEDURE).
Who is sponsoring clinical trial NCT00274638?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.